Jiangxi Fushine Pharmaceutical (300497.SZ): Currently, the company has achieved an annual production capacity of 1200 tons of microbial protein.

Gelonghui Finance · Nov 14 15:04

On November 14, Glonghui reported that jiangxi fushine pharmaceutical (300497.SZ) announced on the investor interaction platform that the company intends to establish jiangxi fushine microbial protein sales companies in shanghai and Singapore to intensify efforts in promoting the sale of microbial protein in various areas on the consumer side. Currently, the company's microbial protein has achieved an annual production capacity of 1,200 tons and is constructing a microbial protein production line with an annual capacity of 0.02 million tons. While consolidating technology and production, the company is also increasing efforts to promote the marketing of microbial protein in various consumer goods. Downstream application scenarios include: health food, functional drinks, dining, special medical food, pet food, etc. The company has received sample and order requests from domestic and international clients and is conducting commercial negotiations with various clients and industrial platforms. Currently, overseas client contacts primarily come from europe, Thailand, Singapore, Malaysia, and other countries and regions. These clients include internationally renowned comprehensive food companies and future food/health food industry platforms. In the international market, microbial protein has entered widely established and relatively mature sales channels and formed a sales scale. The company plans to strengthen links with overseas markets through the newly established shanghai sales company and Singapore sales company by introducing sales talent in the food & beverage and other consumer goods fields, and to enhance collaboration with internationally advanced protein consumer goods application companies, promoting the rapid formation of large-scale sales in the overseas market. In the domestic market, the company is systematically advancing the declaration of new food raw materials and believes that by establishing the shanghai sales company, it will not only attract food and beverage application research and development talent but also drive the microbial protein raw material to form broader application scenarios through forward-looking research and development of C-end products, which will further lay a foundation for B-end sales. According to the progress of the domestic new food raw material application declaration, the company will intensify efforts to promote cooperation between relevant products and sales channels.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

富祥药业(300497.SZ)：目前公司微生物蛋白已实现1200吨/年产能

Jiangxi Fushine Pharmaceutical (300497.SZ): Currently, the company has achieved an annual production capacity of 1200 tons of microbial protein.

Risk Disclaimer

Statement